newsfilter
← Latest News
GlobeNewswire·

Press Release: Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages

  • Sanofi's next-generation rabies vaccine VaxRabeo received European Commission approval on November 19, 2026, for pre-exposure & post-exposure prophylaxis across all age groups.
  • VaxRabeo utilizes state-of-the-art Vero-cell technology & the inactivated Wistar viral strain, sharing the same strain as Sanofi's existing Verorab & Imovax Rabies vaccines.
  • The vaccine features improved thermostability, maintaining stability at temperatures up to 27°C for 96 hours, & has a 60-month shelf life.
  • Clinical trials demonstrated VaxRabeo achieved protective antibody levels comparable to Sanofi's current standard of care vaccines in both pre-exposure & post-exposure settings.
  • VaxRabeo supports flexible WHO-recommended schedules, including a 2-dose pre-exposure regimen & a 4-dose post-exposure regimen for unvaccinated individuals.
  • Booster doses administered 12 or 24–36 months after initial pre-exposure vaccination showed high boostability with no significant safety concerns identified.
  • Rabies remains a fatal viral zoonotic disease present in 150 countries, causing approximately 59,000 deaths annually, with children under 15 accounting for 40% of bite cases.
  • The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use adopted on September 17, 2026.
Company
Sanofi Winthrop Industrie
Keywords
Paris Stock Exchange:SAN, Sanofi Winthrop Industrie